Trials / Completed
CompletedNCT00160576
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- —
Summary
This is a 41-week trial composed of two consecutive parts (Part A, 14 weeks and optional Part B, 27 weeks) to evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with Idiopathic Parkinson's Disease, without negative impact on the benefit on the motor function of the antiparkinsonian treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2004-11-01
- Completion
- 2004-11-01
- First posted
- 2005-09-12
- Last updated
- 2013-12-06
Source: ClinicalTrials.gov record NCT00160576. Inclusion in this directory is not an endorsement.